Harmony Pharma (HRMY): קונצנזוס שווי הוגן

Harmony Biosciences (HRMY) generates revenue from the sale of an exclusive narcolepsy treatment, where minimal outsourcing production costs combined with a high product price create massive liquidity. A steady cash flow is ensured by the fact that the therapy becomes a habit for patients. The current consensus forecast stands at 48.32, while the growth of Wakix is already priced in. This chart illustrates the price action for the company.

This indicator reflects the arithmetic mean of professional analysts' expectations regarding the asset's fair value. The trend in calculated values is based on the updating of investment banks' discounted cash flow models. By analyzing the weighted average price target of the stock, an investor determines the degree of the security's undervaluation. For Harmony Biosciences (HRMY), such forecasts rely on high business margins. A monopoly position in the sleep therapy segment ensures a steady inflow of capital, sustaining expert optimism.